Photobiomodulation therapy in the management of chronic oral graft-versus-host disease

Epstein, Joel B.; Raber-Durlacher, Judith E.; Lill, Michael; Linhares, Yuliya; Chang, Jerry C.; Barasch, Andrei; Slief, Romée I. C; Geuke, Margot; Zecha, Judith A. E. M.; Milstein, Dan M.J.; Tzachanis, Dimitrios

doi:10.1007/s00520-016-3401-1

Cited by 27 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based upon this, PBM has been utilized for local treatment of oral GVHD in patients with continuing symptoms and signs despite systemic and topical therapies with corticosteroids and other immunosuppressants. Two reports of patients who were treated with PBM showed mucosal lichenoid change; particularly, ulceration and erythema were improved in 3-4 weeks of treatment and oral pain, and dry mouth improved in most patients ( 221 , 222 ). These findings suggest that PBM may represent an additional approach for the management of oral GVHD and suggest that controlled studies should be conducted to confirm the efficacy of PBM therapy in oral GVHD and to determine optimal PBM therapy protocols.…”

Section: Resultsmentioning

confidence: 98%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

Self Cite

View full text Add to dashboard Cite

DisclaimerThis article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols.ObjectiveThis position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).BackgroundThere is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care.MethodsA literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed.ResultsThere is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors.ConclusionsThere is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.

show abstract

Section: Resultsmentioning

confidence: 98%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…PBM is already part of the official guidelines for the treatment of OM and is routinely used at hematological and oncological clinics [11,12,18]. Clinical studies also support the use of PBM for other toxicities induced by chemotherapy/radiotherapy including lymphedema, radiodermatitis, osteonecrosis of the jaw, and peripheral neuropathy [7,19,20] as well as oral manifestations of chronic graft versus host disease following allogeneic hematopoietic stem cell transplantation [21,22]. However, all previous reports related to treatments performed by the professional medical team at the clinic.…”

Section: Discussionmentioning

confidence: 99%

Supportive care of cancer patients with a self-applied photobiomodulation device: a case series

Gavish

Zadik

Raizman

2021

Support Care Cancer

View full text Add to dashboard Cite

Purpose Oral mucositis (OM) and prolonged wound healing are common side-effects of cancer treatments. Photobiomodulation (PBM), previously called low-level laser, is currently part of the official guideline for OM prevention. However, all the PBM protocols relate to office-based devices, operated by professional health caregivers, requiring frequent applications. In the following case series, we present our experience with a self-applied consumer home-use PBM device for supportive care. Methods Five patients receiving cancer treatment presented at the clinic (female:male 3:2, 55-76 years old) with OM grade 3/4 (n=2), post-surgical non-healing wounds (n=3), and dermatitis (n=1). The PBM treatment (808 nm, 250 mW peak power, 15KHz, 5 J/min, ray size 4.5×1.0cm 2 ) was self-applied by the patients. The protocol included extra/intra-oral applications, over the wound bed/margins and adjacent lymph nodes. Results The treatment was found effective for resolving OM with rapid pain relief and accelerated healing in post-operative wounds and dermatitis, without reported adverse events. Patients found routine easy to follow and painless, and the protocol was easily integrated as an adjuvant treatment to standard care at the clinic or home while not requiring additional time from the staff. Conclusions Side-effects induced by cancer therapy have a detrimental effect on the patient's well-being and may delay or even prevent the patients from completing treatment regimens. PBM is already an established tool for supportive treatment in cancer patients. The advent of a self-applied personal PBM treatment with easy-to-apply protocols for a variety of side-effects makes this technology an important accessible and safe supportive care option.

show abstract

“…[7][8][9] Also the potential application of PBM for management of xerostomia, dysgeusia, radiodermatitis, post-RT fibrosis, chronic oral graft-versus-host disease (GVHD), and breast cancer-related lymphedema has been reported. [10][11][12][13][14][15][16][17] The basic principle of supportive care in cancer is to provide effective management of complications of cancer treatment without compromising or inducing negative effects on oncology outcomes; also bearing in mind unwanted and dire consequences such as tumor persistence, new secondary tumors, or recurrence of the primary disease. Various in vitro studies have suggested that PBM may induce accelerated growth in some malignant cell lines and/or development of malignancy in dysplastic cells.…”

Section: Introductionmentioning

confidence: 99%

“…PBM also has beneficial effects in the management of soft tissue necrosis in patients with head and neck cancer (HNC), and therapy‐induced bone necrosis 7‐9 . Also the potential application of PBM for management of xerostomia, dysgeusia, radiodermatitis, post‐RT fibrosis, chronic oral graft‐versus‐host disease (GVHD), and breast cancer‐related lymphedema has been reported 10‐17 …”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of photobiomodulation therapy in oncology: A systematic review

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Photobiomodulation therapy in the management of chronic oral graft-versus-host disease

Cited by 27 publications

References 24 publications

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

Supportive care of cancer patients with a self-applied photobiomodulation device: a case series

Safety and efficacy of photobiomodulation therapy in oncology: A systematic review

Contact Info

Product

Resources

About